FDA OKs emergency use of Gilead’s remdesivir for moderate COVID-19

Gilead Sciences (NASDAQ:GILD) announces the FDA emergency use nod for Veklury (remdesivir) for the treatment of hospitalized COVID-19 patients with moderate pneumonia.

It was approved for the emergency treatment of severely ill patients on May 1.

The expanded use was based on results from the Phase 3 SIMPLE study and an NIAID trial in hospitalized patients with a range of disease severity.

https://seekingalpha.com/news/3609893-fda-oks-emergency-use-of-gileads-remdesivir-for-moderate-covidminus-19